Parallel Advisors
LXRX icon

Parallel Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Parallel Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$463 Hold
247
– – ﹤0.01% 3919
2026
Q2 		$593 Hold
247
– – ﹤0.01% 3769
2026
Q1 		$385 Buy
+247
New +$359 ﹤0.01% 3714
2018
Q1 		– Sell
-198
Closed -$2K – 2136
2017
Q4 		$2K Buy
+198
New +$2.06K ﹤0.01% 1861

Other funds holding LXRX

Compagnie Lombard Odier SCmA
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.8B AUM 25.65% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Scheeler Financial
Scheeler Financial West Chester, Ohio $132M AUM
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
University of Texas/Texas AM Investment Management Co (UTIMCO)
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $798M AUM 22.92% 1-Year Est. Return
Straight Path Wealth Management
Straight Path Wealth Management Jenison, Michigan $449M AUM 10.17% 1-Year Est. Return
Arizona State Retirement System
Arizona State Retirement System Phoenix, Arizona $20.3B AUM 36.55% 1-Year Est. Return
Virginia Retirement Systems
Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Pinnacle Associates
Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Parallel Advisors's LXRX Position: Q3 2026 in Review

Parallel Advisors held its Lexicon Pharmaceuticals (LXRX) position steady in Q3 2026 at 247 shares worth $463. The position accounts for ﹤0.01% of the portfolio, ranked #3919.

Parallel Advisors first reported a position in LXRX in Q4 2017 and has held it in 4 quarters since. The position peaked at $2K in Q4 2017. 38 funds tracked by Wall St. Rank hold LXRX as of Q3 2026.

  • Parallel Advisors held 247 shares of Lexicon Pharmaceuticals worth $463 as of Q3 2026.
  • Parallel Advisors left its Lexicon Pharmaceuticals share count unchanged in Q3 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3919 holding.
  • Parallel Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2017 and has held it in 4 quarters since.
  • Parallel Advisors's Lexicon Pharmaceuticals position peaked at $2K in Q4 2017.
  • 38 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.